<DOC>
	<DOCNO>NCT00476996</DOCNO>
	<brief_summary>This study evaluate efficacy safety ocrelizumab , compare placebo , patient active rheumatoid arthritis inadequate response least one anti-TNF-alpha therapy . Patients randomize receive placebo , 200mg intravenous ocrelizumab , 500mg i.v . ocrelizumab day 1 15 . A repeat course i.v . treatment administer week 24 26 . All patient receive stable dos either concomitant methotrexate ( 7.5-25mg/week ) leflunomide ( 10-20mg po daily ) may receive additional DMARDs . The anticipated time study treatment 1-2 year . Target sample size 1000 .</brief_summary>
	<brief_title>A Study Ocrelizumab Compared Placebo Patients With Active Rheumatoid Arthritis Who Do n't Have Response Anti-TNF-α Therapy ( SCRIPT )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>Adult patient , ≥ 18 year age Rheumatoid arthritis ≥ 3 month Inadequate response previous current treatment least one antiTNFalpha agent Receiving either leflunomide methotrexate ≥ 12 week , stable dose last 4 week Rheumatic autoimmune disease inflammatory joint disease , RA Any surgical procedure past 12 week , plan within 48 week baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>RA</keyword>
	<keyword>SCRIPT</keyword>
	<keyword>anti-CD20</keyword>
	<keyword>CD20</keyword>
</DOC>